Zhejiang Medicine Co (600216) Fair Value & Analysis

Healthcare · CN · Market cap 11.5B CNY

Analysis

Zhejiang Medicine Co (600216) currently trades at ¥11.71, while our model-based Fair Value estimate is ¥19.98 — implying the stock looks roughly 70.6% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicoplanin products. The company was incorporated in 1997 and is based in Shaoxing, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.